| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 148 | 2024 | 1676 | 11.600 |
Why?
|
| Immunotherapy, Adoptive | 103 | 2024 | 801 | 10.390 |
Why?
|
| Receptors, Antigen, T-Cell | 52 | 2024 | 477 | 7.580 |
Why?
|
| Genetic Therapy | 77 | 2024 | 678 | 7.430 |
Why?
|
| T-Lymphocytes, Cytotoxic | 90 | 2024 | 501 | 6.260 |
Why?
|
| Gene Transfer Techniques | 59 | 2015 | 357 | 5.220 |
Why?
|
| Bone Marrow Transplantation | 105 | 2014 | 577 | 4.970 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 67 | 2023 | 1198 | 4.440 |
Why?
|
| Genetic Vectors | 78 | 2022 | 940 | 4.330 |
Why?
|
| Caspase 9 | 15 | 2016 | 75 | 4.250 |
Why?
|
| Neoplasms | 56 | 2024 | 2757 | 3.700 |
Why?
|
| Interleukin-2 | 42 | 2015 | 229 | 3.500 |
Why?
|
| Immunotherapy | 41 | 2023 | 653 | 3.410 |
Why?
|
| Herpesvirus 4, Human | 79 | 2024 | 659 | 3.390 |
Why?
|
| Adenoviridae | 45 | 2023 | 608 | 3.360 |
Why?
|
| Neuroblastoma | 31 | 2017 | 509 | 3.040 |
Why?
|
| Recombinant Fusion Proteins | 31 | 2018 | 766 | 2.950 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 23 | 2021 | 183 | 2.880 |
Why?
|
| Graft vs Host Disease | 45 | 2023 | 542 | 2.810 |
Why?
|
| Antigens, Neoplasm | 29 | 2021 | 388 | 2.550 |
Why?
|
| Genes, Transgenic, Suicide | 13 | 2016 | 49 | 2.500 |
Why?
|
| Cancer Vaccines | 19 | 2016 | 186 | 2.370 |
Why?
|
| Cell- and Tissue-Based Therapy | 13 | 2023 | 157 | 2.350 |
Why?
|
| CD40 Ligand | 15 | 2011 | 64 | 2.260 |
Why?
|
| Antibodies, Monoclonal | 37 | 2021 | 1007 | 2.200 |
Why?
|
| Leukemia, Myeloid, Acute | 28 | 2021 | 532 | 2.040 |
Why?
|
| Transgenes | 22 | 2018 | 334 | 1.970 |
Why?
|
| Hematopoietic Stem Cells | 38 | 2007 | 533 | 1.950 |
Why?
|
| Genetic Markers | 35 | 2007 | 609 | 1.900 |
Why?
|
| Stem Cell Transplantation | 19 | 2020 | 239 | 1.840 |
Why?
|
| Retroviridae | 34 | 2022 | 194 | 1.820 |
Why?
|
| Hematologic Neoplasms | 17 | 2024 | 286 | 1.800 |
Why?
|
| Humans | 469 | 2024 | 123163 | 1.780 |
Why?
|
| Lymphocyte Activation | 51 | 2021 | 676 | 1.770 |
Why?
|
| Leukemia | 31 | 2023 | 375 | 1.720 |
Why?
|
| Hodgkin Disease | 26 | 2020 | 293 | 1.680 |
Why?
|
| Adoptive Transfer | 22 | 2016 | 237 | 1.630 |
Why?
|
| Lymphocyte Depletion | 24 | 2024 | 123 | 1.610 |
Why?
|
| Oncolytic Virotherapy | 8 | 2023 | 83 | 1.590 |
Why?
|
| Transduction, Genetic | 33 | 2017 | 290 | 1.590 |
Why?
|
| Cytotoxicity, Immunologic | 31 | 2024 | 262 | 1.560 |
Why?
|
| Genetic Engineering | 11 | 2018 | 161 | 1.500 |
Why?
|
| Epstein-Barr Virus Infections | 25 | 2024 | 285 | 1.460 |
Why?
|
| Transplantation Conditioning | 18 | 2019 | 323 | 1.410 |
Why?
|
| Cell Engineering | 5 | 2020 | 21 | 1.400 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2022 | 86 | 1.390 |
Why?
|
| Transplantation, Homologous | 47 | 2021 | 659 | 1.360 |
Why?
|
| Gene Expression | 23 | 2017 | 1566 | 1.330 |
Why?
|
| Lymphoma | 19 | 2023 | 321 | 1.330 |
Why?
|
| Antigens, CD19 | 21 | 2024 | 177 | 1.320 |
Why?
|
| Apoptosis | 17 | 2024 | 1781 | 1.300 |
Why?
|
| Killer Cells, Natural | 23 | 2023 | 319 | 1.210 |
Why?
|
| Animals | 125 | 2024 | 33752 | 1.200 |
Why?
|
| Antigens, CD | 16 | 2015 | 421 | 1.200 |
Why?
|
| Interleukin-12 | 9 | 2021 | 113 | 1.160 |
Why?
|
| Periodicals as Topic | 4 | 2014 | 195 | 1.150 |
Why?
|
| Xenograft Model Antitumor Assays | 23 | 2024 | 877 | 1.120 |
Why?
|
| Cell Line, Tumor | 41 | 2024 | 3273 | 1.100 |
Why?
|
| Leukocyte Common Antigens | 10 | 2023 | 90 | 1.090 |
Why?
|
| Oncolytic Viruses | 6 | 2024 | 71 | 1.050 |
Why?
|
| CD5 Antigens | 7 | 2024 | 37 | 1.050 |
Why?
|
| Pancreatic Neoplasms | 5 | 2024 | 673 | 1.010 |
Why?
|
| Transplantation, Autologous | 34 | 2020 | 296 | 0.990 |
Why?
|
| Lymphoproliferative Disorders | 16 | 2015 | 224 | 0.920 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 2019 | 162 | 0.920 |
Why?
|
| B-Lymphocytes | 35 | 2013 | 518 | 0.920 |
Why?
|
| Virus Diseases | 11 | 2020 | 280 | 0.900 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2023 | 148 | 0.900 |
Why?
|
| Gangliosides | 5 | 2024 | 63 | 0.890 |
Why?
|
| Mice | 78 | 2024 | 17492 | 0.880 |
Why?
|
| T-Lymphocyte Subsets | 12 | 2014 | 193 | 0.880 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2015 | 190 | 0.860 |
Why?
|
| Virus Replication | 9 | 2022 | 603 | 0.850 |
Why?
|
| Cytokines | 27 | 2024 | 1285 | 0.850 |
Why?
|
| Musa | 1 | 2023 | 3 | 0.850 |
Why?
|
| Tumor Necrosis Factor-alpha | 18 | 2020 | 667 | 0.840 |
Why?
|
| Dendritic Cells | 18 | 2010 | 403 | 0.840 |
Why?
|
| Flow Cytometry | 22 | 2016 | 803 | 0.840 |
Why?
|
| Lymphoma, B-Cell | 9 | 2019 | 136 | 0.830 |
Why?
|
| Tumor Escape | 8 | 2018 | 61 | 0.830 |
Why?
|
| Publishing | 3 | 2014 | 108 | 0.820 |
Why?
|
| Combined Modality Therapy | 18 | 2024 | 1239 | 0.810 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 3 | 2024 | 25 | 0.790 |
Why?
|
| Receptor, ErbB-2 | 9 | 2024 | 494 | 0.790 |
Why?
|
| CD8-Positive T-Lymphocytes | 15 | 2020 | 394 | 0.780 |
Why?
|
| Tumor Microenvironment | 10 | 2024 | 530 | 0.780 |
Why?
|
| Male | 147 | 2024 | 60082 | 0.780 |
Why?
|
| Adolescent | 101 | 2024 | 19102 | 0.770 |
Why?
|
| Leukemia, Myeloid | 14 | 2006 | 85 | 0.760 |
Why?
|
| Female | 147 | 2024 | 65489 | 0.760 |
Why?
|
| Child | 111 | 2024 | 24234 | 0.760 |
Why?
|
| Neoplastic Stem Cells | 10 | 2011 | 294 | 0.750 |
Why?
|
| Cell Proliferation | 27 | 2024 | 2306 | 0.740 |
Why?
|
| Child, Preschool | 75 | 2024 | 13886 | 0.730 |
Why?
|
| Helper Viruses | 1 | 2021 | 45 | 0.730 |
Why?
|
| Interferon-gamma | 21 | 2013 | 510 | 0.720 |
Why?
|
| Cytomegalovirus | 20 | 2017 | 268 | 0.720 |
Why?
|
| Graft vs Leukemia Effect | 4 | 2021 | 30 | 0.710 |
Why?
|
| Tumor Cells, Cultured | 33 | 2008 | 1061 | 0.690 |
Why?
|
| Lung Neoplasms | 4 | 2021 | 1582 | 0.690 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2024 | 1117 | 0.680 |
Why?
|
| CD4-Positive T-Lymphocytes | 16 | 2020 | 473 | 0.670 |
Why?
|
| Lymphocyte Transfusion | 7 | 2021 | 57 | 0.670 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 19 | 2019 | 804 | 0.670 |
Why?
|
| Dependovirus | 1 | 2021 | 130 | 0.670 |
Why?
|
| Autoimmune Diseases | 7 | 2018 | 250 | 0.670 |
Why?
|
| Antibody Formation | 13 | 2009 | 256 | 0.660 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2017 | 105 | 0.650 |
Why?
|
| Medical Oncology | 4 | 2018 | 214 | 0.650 |
Why?
|
| Interleukin-15 | 6 | 2024 | 91 | 0.640 |
Why?
|
| Membrane Glycoproteins | 7 | 2005 | 413 | 0.640 |
Why?
|
| Multiple Myeloma | 10 | 2020 | 169 | 0.630 |
Why?
|
| Treatment Outcome | 50 | 2024 | 12129 | 0.630 |
Why?
|
| Molecular Targeted Therapy | 4 | 2017 | 353 | 0.620 |
Why?
|
| Recurrence | 29 | 2023 | 1422 | 0.620 |
Why?
|
| Adult | 100 | 2024 | 29057 | 0.620 |
Why?
|
| Antibodies, Neoplasm | 10 | 2017 | 58 | 0.610 |
Why?
|
| Viruses | 2 | 2016 | 123 | 0.610 |
Why?
|
| Antineoplastic Agents | 21 | 2017 | 1661 | 0.600 |
Why?
|
| Lymphocytes | 17 | 2023 | 401 | 0.590 |
Why?
|
| Bone Marrow Cells | 20 | 2007 | 258 | 0.590 |
Why?
|
| Coculture Techniques | 15 | 2021 | 233 | 0.580 |
Why?
|
| Leukemia, Hairy Cell | 8 | 1993 | 16 | 0.580 |
Why?
|
| Transfection | 17 | 2012 | 1068 | 0.570 |
Why?
|
| Antibodies, Bispecific | 3 | 2024 | 33 | 0.570 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2014 | 216 | 0.570 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 69 | 0.560 |
Why?
|
| Immunophenotyping | 26 | 2023 | 330 | 0.560 |
Why?
|
| Mice, SCID | 20 | 2021 | 571 | 0.550 |
Why?
|
| Cells, Cultured | 33 | 2020 | 3044 | 0.540 |
Why?
|
| Lymphocyte Subsets | 4 | 2017 | 38 | 0.540 |
Why?
|
| Tissue Donors | 16 | 2021 | 496 | 0.530 |
Why?
|
| Lymphokines | 7 | 2007 | 66 | 0.530 |
Why?
|
| Lymphoma, T-Cell | 4 | 2024 | 64 | 0.520 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 99 | 0.520 |
Why?
|
| Cell Line | 30 | 2022 | 2771 | 0.510 |
Why?
|
| Cell Survival | 16 | 2018 | 806 | 0.510 |
Why?
|
| Divorce | 1 | 2015 | 6 | 0.510 |
Why?
|
| Viral Matrix Proteins | 11 | 2018 | 109 | 0.500 |
Why?
|
| Marriage | 1 | 2015 | 29 | 0.500 |
Why?
|
| Glial Fibrillary Acidic Protein | 11 | 2011 | 104 | 0.500 |
Why?
|
| CD28 Antigens | 7 | 2024 | 78 | 0.500 |
Why?
|
| Genes, Reporter | 8 | 2015 | 384 | 0.500 |
Why?
|
| Middle Aged | 61 | 2024 | 25992 | 0.490 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 5 | 2021 | 80 | 0.490 |
Why?
|
| Family Relations | 1 | 2015 | 69 | 0.480 |
Why?
|
| Bone Neoplasms | 4 | 2015 | 427 | 0.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 332 | 0.480 |
Why?
|
| Ki-1 Antigen | 4 | 2020 | 27 | 0.470 |
Why?
|
| Organic Chemicals | 6 | 2015 | 59 | 0.440 |
Why?
|
| Sialoglycoproteins | 4 | 2007 | 48 | 0.440 |
Why?
|
| Recombinant Proteins | 19 | 2015 | 1386 | 0.430 |
Why?
|
| Stress, Psychological | 2 | 2015 | 556 | 0.430 |
Why?
|
| Social Support | 1 | 2015 | 344 | 0.430 |
Why?
|
| Leukemia, B-Cell | 4 | 2010 | 26 | 0.420 |
Why?
|
| Bone Marrow Purging | 11 | 2007 | 34 | 0.420 |
Why?
|
| Cell Differentiation | 13 | 2015 | 1907 | 0.420 |
Why?
|
| Clinical Trials as Topic | 16 | 2016 | 1088 | 0.420 |
Why?
|
| Young Adult | 21 | 2024 | 8862 | 0.420 |
Why?
|
| Cytomegalovirus Infections | 8 | 2013 | 217 | 0.420 |
Why?
|
| Herpesviridae Infections | 11 | 2013 | 142 | 0.410 |
Why?
|
| Salvage Therapy | 4 | 2021 | 193 | 0.410 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 202 | 0.410 |
Why?
|
| Interleukin-4 | 8 | 2018 | 138 | 0.410 |
Why?
|
| Journal Impact Factor | 1 | 2012 | 22 | 0.410 |
Why?
|
| Congenital Abnormalities | 1 | 2015 | 249 | 0.410 |
Why?
|
| Growth Substances | 6 | 1996 | 113 | 0.400 |
Why?
|
| Graft Rejection | 10 | 2020 | 582 | 0.400 |
Why?
|
| Tacrolimus Binding Proteins | 2 | 2011 | 66 | 0.390 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2003 | 98 | 0.390 |
Why?
|
| Stem Cells | 10 | 2014 | 700 | 0.390 |
Why?
|
| Antigen-Presenting Cells | 7 | 2007 | 118 | 0.390 |
Why?
|
| Stem Cell Research | 1 | 2011 | 6 | 0.390 |
Why?
|
| Bone Marrow | 12 | 2020 | 323 | 0.380 |
Why?
|
| Antigens, Viral | 15 | 2013 | 435 | 0.380 |
Why?
|
| Disease Models, Animal | 11 | 2020 | 4275 | 0.380 |
Why?
|
| B7-H1 Antigen | 4 | 2021 | 97 | 0.380 |
Why?
|
| Vidarabine | 7 | 2024 | 79 | 0.380 |
Why?
|
| CD3 Complex | 10 | 2015 | 82 | 0.380 |
Why?
|
| Bibliometrics | 1 | 2011 | 29 | 0.370 |
Why?
|
| Immunosuppressive Agents | 10 | 2015 | 644 | 0.370 |
Why?
|
| Chemokines, C | 3 | 2002 | 10 | 0.370 |
Why?
|
| Biomedical Research | 2 | 2014 | 518 | 0.370 |
Why?
|
| Epitopes, T-Lymphocyte | 7 | 2014 | 125 | 0.370 |
Why?
|
| Glioblastoma | 4 | 2017 | 334 | 0.360 |
Why?
|
| Epitopes | 7 | 2020 | 429 | 0.360 |
Why?
|
| Cell Transplantation | 6 | 2016 | 45 | 0.360 |
Why?
|
| Biological Therapy | 1 | 2010 | 20 | 0.360 |
Why?
|
| Infant | 40 | 2024 | 12347 | 0.350 |
Why?
|
| Aged | 30 | 2024 | 19080 | 0.350 |
Why?
|
| Histocompatibility | 6 | 2006 | 46 | 0.350 |
Why?
|
| Interleukin-7 | 4 | 2017 | 43 | 0.340 |
Why?
|
| Drug Resistance | 11 | 2009 | 256 | 0.340 |
Why?
|
| T-Cell Antigen Receptor Specificity | 6 | 2021 | 58 | 0.340 |
Why?
|
| Leber Congenital Amaurosis | 1 | 2010 | 30 | 0.340 |
Why?
|
| Lentivirus | 6 | 2017 | 83 | 0.340 |
Why?
|
| Thrombocytopenia | 4 | 2024 | 228 | 0.340 |
Why?
|
| Receptors, Antigen | 1 | 2009 | 34 | 0.340 |
Why?
|
| Immunization | 7 | 2010 | 308 | 0.330 |
Why?
|
| Simplexvirus | 6 | 2003 | 105 | 0.330 |
Why?
|
| Leukocytes, Mononuclear | 14 | 2023 | 326 | 0.330 |
Why?
|
| Remission Induction | 15 | 2020 | 300 | 0.330 |
Why?
|
| Myeloid Cells | 4 | 2018 | 98 | 0.330 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 2527 | 0.320 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2830 | 0.320 |
Why?
|
| Recoverin | 1 | 2008 | 10 | 0.320 |
Why?
|
| Cell Separation | 14 | 2018 | 232 | 0.320 |
Why?
|
| Alemtuzumab | 8 | 2018 | 88 | 0.320 |
Why?
|
| Precision Medicine | 1 | 2012 | 312 | 0.310 |
Why?
|
| Astrocytes | 9 | 2001 | 251 | 0.310 |
Why?
|
| Immunotoxins | 4 | 2015 | 21 | 0.310 |
Why?
|
| Killer Cells, Lymphokine-Activated | 4 | 1993 | 10 | 0.310 |
Why?
|
| Lymphocyte Count | 5 | 2018 | 114 | 0.310 |
Why?
|
| Nasopharyngeal Neoplasms | 5 | 2024 | 57 | 0.300 |
Why?
|
| Adenoviridae Infections | 5 | 2013 | 70 | 0.300 |
Why?
|
| Sarcoma | 2 | 2024 | 194 | 0.300 |
Why?
|
| Osteogenesis Imperfecta | 2 | 2001 | 148 | 0.290 |
Why?
|
| Phenotype | 15 | 2018 | 4227 | 0.290 |
Why?
|
| Virus Integration | 4 | 2015 | 42 | 0.290 |
Why?
|
| Liposomes | 4 | 2004 | 168 | 0.290 |
Why?
|
| Cyclophosphamide | 8 | 2024 | 419 | 0.290 |
Why?
|
| Neoplasm Proteins | 6 | 2018 | 667 | 0.280 |
Why?
|
| Haplotypes | 4 | 2015 | 519 | 0.280 |
Why?
|
| Polymerase Chain Reaction | 15 | 2008 | 1584 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1227 | 0.280 |
Why?
|
| Cell Division | 15 | 2006 | 780 | 0.280 |
Why?
|
| Mice, Inbred NOD | 9 | 2021 | 285 | 0.270 |
Why?
|
| Brain Neoplasms | 5 | 2021 | 1235 | 0.270 |
Why?
|
| Immunization, Passive | 9 | 2001 | 118 | 0.270 |
Why?
|
| Herpesvirus 6, Human | 4 | 2017 | 58 | 0.270 |
Why?
|
| RNA, Messenger | 14 | 2009 | 2814 | 0.270 |
Why?
|
| Models, Immunological | 4 | 2010 | 35 | 0.270 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 4 | 2014 | 60 | 0.270 |
Why?
|
| Glycoproteins | 3 | 2022 | 369 | 0.270 |
Why?
|
| Membrane Proteins | 3 | 2003 | 1530 | 0.260 |
Why?
|
| HLA Antigens | 6 | 2010 | 243 | 0.260 |
Why?
|
| Recovery of Function | 2 | 2005 | 437 | 0.260 |
Why?
|
| Hematopoiesis | 7 | 2011 | 216 | 0.260 |
Why?
|
| Receptors, Cell Surface | 4 | 2004 | 468 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2010 | 714 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2016 | 813 | 0.250 |
Why?
|
| DNA Viruses | 2 | 2017 | 33 | 0.250 |
Why?
|
| Antigen Presentation | 9 | 2010 | 105 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2017 | 1683 | 0.250 |
Why?
|
| CD8 Antigens | 4 | 2020 | 40 | 0.250 |
Why?
|
| Glioma | 6 | 2024 | 496 | 0.250 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2011 | 38 | 0.240 |
Why?
|
| ATP-Binding Cassette Transporters | 4 | 2010 | 187 | 0.240 |
Why?
|
| Roseolovirus Infections | 3 | 2012 | 33 | 0.240 |
Why?
|
| Tumor Necrosis Factors | 1 | 2004 | 12 | 0.240 |
Why?
|
| Carboplatin | 2 | 2024 | 75 | 0.240 |
Why?
|
| Granulomatous Disease, Chronic | 2 | 2018 | 65 | 0.240 |
Why?
|
| Cellular Senescence | 3 | 2024 | 161 | 0.240 |
Why?
|
| Enzyme Activation | 4 | 2015 | 617 | 0.230 |
Why?
|
| Transplantation Chimera | 5 | 2015 | 39 | 0.230 |
Why?
|
| Receptors, Interleukin-7 | 4 | 2014 | 22 | 0.230 |
Why?
|
| Mutant Chimeric Proteins | 3 | 2017 | 16 | 0.230 |
Why?
|
| Glypicans | 1 | 2024 | 39 | 0.230 |
Why?
|
| Autoantigens | 2 | 2004 | 119 | 0.230 |
Why?
|
| Immunologic Memory | 8 | 2011 | 180 | 0.230 |
Why?
|
| Deoxycytidine | 1 | 2024 | 75 | 0.230 |
Why?
|
| Tumor Virus Infections | 9 | 1998 | 134 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2016 | 490 | 0.230 |
Why?
|
| Time Factors | 20 | 2018 | 6217 | 0.230 |
Why?
|
| Prodrugs | 4 | 2016 | 59 | 0.230 |
Why?
|
| Immunity | 4 | 2009 | 182 | 0.220 |
Why?
|
| DNA Virus Infections | 2 | 2017 | 22 | 0.220 |
Why?
|
| Clinical Protocols | 10 | 2000 | 235 | 0.220 |
Why?
|
| A549 Cells | 2 | 2021 | 44 | 0.220 |
Why?
|
| Central Nervous System Diseases | 2 | 2002 | 105 | 0.220 |
Why?
|
| Immunocompromised Host | 7 | 2014 | 300 | 0.210 |
Why?
|
| Antigens, CD34 | 9 | 2001 | 108 | 0.210 |
Why?
|
| Neoplasm Transplantation | 8 | 2023 | 369 | 0.210 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2024 | 194 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2021 | 137 | 0.210 |
Why?
|
| Complement Activation | 1 | 2003 | 52 | 0.210 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 1997 | 66 | 0.210 |
Why?
|
| Plasmids | 7 | 2011 | 509 | 0.210 |
Why?
|
| Lectins | 1 | 2023 | 49 | 0.210 |
Why?
|
| Acute Disease | 11 | 2011 | 1094 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.210 |
Why?
|
| Tacrolimus Binding Protein 1A | 2 | 2015 | 20 | 0.210 |
Why?
|
| Fibroblasts | 8 | 2004 | 878 | 0.210 |
Why?
|
| Follow-Up Studies | 14 | 2022 | 5046 | 0.210 |
Why?
|
| Blood Component Removal | 1 | 2002 | 32 | 0.210 |
Why?
|
| Plasmacytoma | 1 | 2002 | 7 | 0.210 |
Why?
|
| Chemotaxis, Leukocyte | 3 | 2010 | 61 | 0.200 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2016 | 31 | 0.200 |
Why?
|
| Mesoderm | 2 | 2001 | 111 | 0.200 |
Why?
|
| Osteoblasts | 2 | 2003 | 149 | 0.200 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 2017 | 30 | 0.200 |
Why?
|
| Survival Analysis | 9 | 2018 | 1472 | 0.200 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2004 | 50 | 0.200 |
Why?
|
| Mice, Transgenic | 4 | 2010 | 2390 | 0.200 |
Why?
|
| Immunoglobulin G | 18 | 2014 | 770 | 0.190 |
Why?
|
| Mice, Inbred BALB C | 7 | 2010 | 1002 | 0.190 |
Why?
|
| Blood Platelets | 2 | 2024 | 333 | 0.190 |
Why?
|
| Drug Carriers | 1 | 2002 | 98 | 0.190 |
Why?
|
| Antigens, CD7 | 3 | 2018 | 11 | 0.190 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2017 | 45 | 0.190 |
Why?
|
| Receptor, EphA2 | 1 | 2021 | 26 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 6 | 2018 | 455 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2007 | 1292 | 0.190 |
Why?
|
| Antigens | 5 | 2014 | 157 | 0.190 |
Why?
|
| Peptides | 5 | 2016 | 794 | 0.190 |
Why?
|
| Busulfan | 3 | 2023 | 44 | 0.190 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2008 | 107 | 0.180 |
Why?
|
| Virus Activation | 6 | 2012 | 86 | 0.180 |
Why?
|
| Leukemia, Experimental | 2 | 1997 | 15 | 0.180 |
Why?
|
| Prostatic Neoplasms | 4 | 2013 | 1515 | 0.180 |
Why?
|
| K562 Cells | 5 | 2011 | 95 | 0.180 |
Why?
|
| Neomycin | 7 | 2000 | 36 | 0.180 |
Why?
|
| Adenoviruses, Human | 6 | 2017 | 81 | 0.180 |
Why?
|
| Viral Tropism | 1 | 2021 | 42 | 0.180 |
Why?
|
| Disease-Free Survival | 9 | 2017 | 861 | 0.180 |
Why?
|
| DNA, Viral | 10 | 2009 | 478 | 0.180 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 21 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 105 | 0.180 |
Why?
|
| Fetal Blood | 4 | 2010 | 177 | 0.180 |
Why?
|
| Signal Transduction | 8 | 2018 | 4493 | 0.180 |
Why?
|
| Anemia | 2 | 2024 | 340 | 0.170 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 1994 | 73 | 0.170 |
Why?
|
| Antigens, Surface | 6 | 2004 | 121 | 0.170 |
Why?
|
| Receptors, Interleukin-2 | 6 | 2005 | 43 | 0.170 |
Why?
|
| Leukemia, Lymphoid | 8 | 1999 | 108 | 0.170 |
Why?
|
| Transplantation Immunology | 4 | 2006 | 53 | 0.160 |
Why?
|
| Histocompatibility Testing | 7 | 2009 | 148 | 0.160 |
Why?
|
| Unrelated Donors | 3 | 2018 | 82 | 0.160 |
Why?
|
| Protein Multimerization | 2 | 2016 | 122 | 0.160 |
Why?
|
| Growth Inhibitors | 4 | 1998 | 37 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 64 | 0.160 |
Why?
|
| Interferon Type I | 5 | 2017 | 107 | 0.160 |
Why?
|
| Feasibility Studies | 6 | 2022 | 751 | 0.160 |
Why?
|
| Green Fluorescent Proteins | 7 | 2014 | 394 | 0.160 |
Why?
|
| Immune Tolerance | 5 | 2004 | 145 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 6 | 2020 | 57 | 0.160 |
Why?
|
| Cell Line, Transformed | 9 | 2010 | 170 | 0.150 |
Why?
|
| Graft Survival | 6 | 2008 | 525 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 622 | 0.150 |
Why?
|
| Tetanus Toxoid | 6 | 1988 | 45 | 0.150 |
Why?
|
| Societies, Scientific | 2 | 2011 | 26 | 0.150 |
Why?
|
| Molecular Sequence Data | 15 | 2013 | 3868 | 0.150 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2017 | 8 | 0.150 |
Why?
|
| 4-1BB Ligand | 1 | 2017 | 11 | 0.150 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 22 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 2010 | 57 | 0.150 |
Why?
|
| Proteins | 1 | 2003 | 1037 | 0.150 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2017 | 31 | 0.150 |
Why?
|
| Immunological Synapses | 1 | 2017 | 26 | 0.150 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 200 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2010 | 617 | 0.140 |
Why?
|
| Immune System | 2 | 2010 | 87 | 0.140 |
Why?
|
| Central Nervous System | 1 | 1999 | 254 | 0.140 |
Why?
|
| Peptide Fragments | 7 | 2011 | 747 | 0.140 |
Why?
|
| Safety | 5 | 2007 | 217 | 0.140 |
Why?
|
| Carcinoma | 2 | 2010 | 278 | 0.140 |
Why?
|
| Whole-Body Irradiation | 5 | 2006 | 65 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2018 | 272 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 96 | 0.140 |
Why?
|
| Clone Cells | 6 | 2008 | 163 | 0.140 |
Why?
|
| History, 20th Century | 2 | 2014 | 383 | 0.140 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 1309 | 0.140 |
Why?
|
| Mucin-1 | 2 | 2013 | 34 | 0.140 |
Why?
|
| Immunoglobulins | 3 | 1992 | 169 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 993 | 0.140 |
Why?
|
| Lymphocyte Cooperation | 6 | 1990 | 11 | 0.140 |
Why?
|
| Educational Status | 2 | 2015 | 270 | 0.140 |
Why?
|
| Ricin | 2 | 1994 | 12 | 0.140 |
Why?
|
| Hemorrhagic Disorders | 1 | 2016 | 17 | 0.140 |
Why?
|
| Platelet Function Tests | 1 | 2016 | 38 | 0.130 |
Why?
|
| Methylprednisolone | 2 | 1995 | 90 | 0.130 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2016 | 20 | 0.130 |
Why?
|
| Chronic Disease | 5 | 2024 | 1168 | 0.130 |
Why?
|
| Injections, Intralesional | 2 | 2015 | 47 | 0.130 |
Why?
|
| Hematocrit | 1 | 2016 | 110 | 0.130 |
Why?
|
| Platelet Count | 1 | 2016 | 133 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 512 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 9 | 2015 | 1339 | 0.130 |
Why?
|
| Dose-Response Relationship, Immunologic | 3 | 2006 | 105 | 0.130 |
Why?
|
| Melanoma | 2 | 2016 | 824 | 0.130 |
Why?
|
| Somatostatin | 1 | 1996 | 69 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 1870 | 0.130 |
Why?
|
| Single-Chain Antibodies | 2 | 2021 | 38 | 0.130 |
Why?
|
| Immunoglobulin M | 10 | 1995 | 210 | 0.130 |
Why?
|
| Base Sequence | 11 | 2001 | 3091 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 233 | 0.130 |
Why?
|
| Living Donors | 3 | 2008 | 112 | 0.130 |
Why?
|
| Fibronectins | 2 | 2015 | 102 | 0.130 |
Why?
|
| Hyaluronan Receptors | 2 | 2020 | 66 | 0.130 |
Why?
|
| Receptors, Virus | 2 | 2010 | 104 | 0.130 |
Why?
|
| Gentamicins | 3 | 1992 | 95 | 0.130 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 650 | 0.130 |
Why?
|
| Quebec | 1 | 2015 | 5 | 0.130 |
Why?
|
| Birth Order | 1 | 2015 | 7 | 0.130 |
Why?
|
| Fibrin | 1 | 2016 | 67 | 0.130 |
Why?
|
| Immunity, Cellular | 5 | 2018 | 203 | 0.130 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 1998 | 221 | 0.130 |
Why?
|
| B7-2 Antigen | 2 | 2005 | 16 | 0.120 |
Why?
|
| Transcription Factors | 3 | 2002 | 2585 | 0.120 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 13 | 0.120 |
Why?
|
| Gene Order | 1 | 2015 | 78 | 0.120 |
Why?
|
| Capsid Proteins | 2 | 2007 | 180 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 1996 | 157 | 0.120 |
Why?
|
| Muromonab-CD3 | 1 | 2015 | 8 | 0.120 |
Why?
|
| Cell Adhesion | 3 | 2012 | 318 | 0.120 |
Why?
|
| Myeloablative Agonists | 1 | 2015 | 25 | 0.120 |
Why?
|
| Mesna | 2 | 1994 | 10 | 0.120 |
Why?
|
| Granulocytes | 3 | 1991 | 65 | 0.120 |
Why?
|
| Phosphoproteins | 3 | 2008 | 399 | 0.120 |
Why?
|
| Antibodies, Bacterial | 4 | 1990 | 382 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 729 | 0.120 |
Why?
|
| Rats | 10 | 2009 | 3654 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2014 | 747 | 0.120 |
Why?
|
| Cell Culture Techniques | 5 | 2010 | 287 | 0.120 |
Why?
|
| Hematopoietic Cell Growth Factors | 2 | 1991 | 10 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 217 | 0.120 |
Why?
|
| Boronic Acids | 1 | 2014 | 48 | 0.120 |
Why?
|
| Postoperative Complications | 8 | 2010 | 3013 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 6371 | 0.120 |
Why?
|
| Siblings | 3 | 2015 | 195 | 0.120 |
Why?
|
| Kinetics | 5 | 2011 | 1313 | 0.120 |
Why?
|
| Mutation | 4 | 2011 | 5773 | 0.120 |
Why?
|
| Antigens, CD20 | 4 | 2006 | 37 | 0.120 |
Why?
|
| Luminescent Proteins | 4 | 2003 | 157 | 0.120 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 8 | 0.120 |
Why?
|
| Pyrazines | 1 | 2014 | 73 | 0.120 |
Why?
|
| Models, Biological | 3 | 2016 | 1441 | 0.110 |
Why?
|
| Skin Ulcer | 1 | 2014 | 32 | 0.110 |
Why?
|
| Speech Acoustics | 1 | 1994 | 8 | 0.110 |
Why?
|
| Thalidomide | 1 | 2014 | 36 | 0.110 |
Why?
|
| Teratoma | 1 | 2015 | 123 | 0.110 |
Why?
|
| Antibodies, Viral | 7 | 2007 | 1135 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2009 | 201 | 0.110 |
Why?
|
| Leukocytes | 2 | 2015 | 207 | 0.110 |
Why?
|
| Risk Factors | 11 | 2017 | 10008 | 0.110 |
Why?
|
| Aphthovirus | 1 | 2013 | 4 | 0.110 |
Why?
|
| Amino Acid Sequence | 9 | 2013 | 2696 | 0.110 |
Why?
|
| Stromal Cells | 2 | 2016 | 294 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2024 | 4705 | 0.110 |
Why?
|
| Tacrolimus | 3 | 2009 | 99 | 0.110 |
Why?
|
| RNA Viruses | 1 | 2013 | 36 | 0.110 |
Why?
|
| Retrospective Studies | 16 | 2022 | 16021 | 0.110 |
Why?
|
| Kanamycin Kinase | 6 | 1998 | 16 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 607 | 0.110 |
Why?
|
| Immunologic Factors | 3 | 2009 | 179 | 0.110 |
Why?
|
| Biomarkers | 5 | 2010 | 2946 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 211 | 0.110 |
Why?
|
| Flutamide | 1 | 2013 | 24 | 0.110 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 19 | 0.110 |
Why?
|
| Integrins | 3 | 2004 | 81 | 0.110 |
Why?
|
| DNA | 7 | 2008 | 1592 | 0.110 |
Why?
|
| Child Development | 1 | 2015 | 261 | 0.100 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1993 | 34 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 481 | 0.100 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 5 | 1997 | 39 | 0.100 |
Why?
|
| Burkitt Lymphoma | 3 | 2006 | 145 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 350 | 0.100 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 55 | 0.100 |
Why?
|
| Oligopeptides | 3 | 2004 | 118 | 0.100 |
Why?
|
| Tumor Burden | 3 | 2021 | 229 | 0.100 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 47 | 0.100 |
Why?
|
| Neoplasm, Residual | 2 | 2011 | 121 | 0.100 |
Why?
|
| Infusions, Intravenous | 7 | 2010 | 536 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 171 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 1994 | 188 | 0.100 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1992 | 26 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 7 | 2010 | 4348 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 651 | 0.100 |
Why?
|
| Cerebellum | 1 | 1996 | 414 | 0.100 |
Why?
|
| Leukocyte Count | 5 | 2002 | 247 | 0.100 |
Why?
|
| Placenta | 1 | 1996 | 493 | 0.100 |
Why?
|
| Nanotechnology | 1 | 2012 | 48 | 0.100 |
Why?
|
| Gold | 1 | 2012 | 48 | 0.100 |
Why?
|
| CD27 Ligand | 1 | 2011 | 5 | 0.100 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2011 | 12 | 0.100 |
Why?
|
| Antilymphocyte Serum | 3 | 2006 | 56 | 0.100 |
Why?
|
| Alexander Disease | 1 | 2011 | 2 | 0.100 |
Why?
|
| Viral Proteins | 3 | 2004 | 348 | 0.100 |
Why?
|
| Ganciclovir | 4 | 2001 | 102 | 0.100 |
Why?
|
| Graft vs Host Reaction | 1 | 1991 | 9 | 0.100 |
Why?
|
| fas Receptor | 2 | 2017 | 41 | 0.100 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 267 | 0.100 |
Why?
|
| Cell Movement | 3 | 2010 | 831 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2012 | 42 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 260 | 0.100 |
Why?
|
| Standard of Care | 1 | 2012 | 129 | 0.100 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 24 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2024 | 6032 | 0.100 |
Why?
|
| Cell Transformation, Viral | 6 | 2003 | 106 | 0.100 |
Why?
|
| Multiple Sclerosis | 3 | 2004 | 335 | 0.090 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 6 | 1993 | 16 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2011 | 752 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2005 | 77 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 254 | 0.090 |
Why?
|
| Peptide Library | 3 | 2011 | 55 | 0.090 |
Why?
|
| Chills | 1 | 2010 | 6 | 0.090 |
Why?
|
| Home Infusion Therapy | 1 | 2010 | 6 | 0.090 |
Why?
|
| Molecular Biology | 1 | 2011 | 77 | 0.090 |
Why?
|
| Receptors, CCR2 | 1 | 2010 | 23 | 0.090 |
Why?
|
| Bone Transplantation | 1 | 1991 | 49 | 0.090 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 20 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 14 | 0.090 |
Why?
|
| Cell Membrane | 2 | 2012 | 459 | 0.090 |
Why?
|
| Pluripotent Stem Cells | 1 | 2011 | 76 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 22 | 0.090 |
Why?
|
| Enzyme Induction | 2 | 2014 | 103 | 0.090 |
Why?
|
| Prognosis | 7 | 2021 | 4507 | 0.090 |
Why?
|
| Osteogenesis | 2 | 2003 | 153 | 0.090 |
Why?
|
| HIV-1 | 3 | 2000 | 465 | 0.090 |
Why?
|
| NF-kappa B | 2 | 2017 | 455 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2004 | 96 | 0.090 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 172 | 0.090 |
Why?
|
| Colony-Stimulating Factors | 1 | 1989 | 3 | 0.090 |
Why?
|
| Heterografts | 2 | 2023 | 179 | 0.090 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1989 | 20 | 0.090 |
Why?
|
| Adult Stem Cells | 1 | 2010 | 53 | 0.090 |
Why?
|
| Genes, Viral | 3 | 2001 | 183 | 0.090 |
Why?
|
| Homeostasis | 2 | 1991 | 682 | 0.080 |
Why?
|
| Blotting, Western | 5 | 2015 | 1100 | 0.080 |
Why?
|
| In Vitro Techniques | 8 | 2016 | 966 | 0.080 |
Why?
|
| Receptors, Immunologic | 3 | 2004 | 110 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 664 | 0.080 |
Why?
|
| Pseudomonas Infections | 1 | 1990 | 114 | 0.080 |
Why?
|
| Receptors, CCR4 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Genetic Techniques | 1 | 2010 | 107 | 0.080 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 147 | 0.080 |
Why?
|
| Adenovirus Infections, Human | 1 | 2009 | 49 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1990 | 164 | 0.080 |
Why?
|
| Genes, Synthetic | 1 | 2009 | 10 | 0.080 |
Why?
|
| Survival Rate | 5 | 2017 | 1996 | 0.080 |
Why?
|
| Aging | 1 | 1996 | 1174 | 0.080 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 1999 | 52 | 0.080 |
Why?
|
| Allografts | 2 | 2021 | 190 | 0.080 |
Why?
|
| Parkinson Disease, Secondary | 2 | 1999 | 20 | 0.080 |
Why?
|
| Fever | 2 | 2010 | 296 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 1005 | 0.080 |
Why?
|
| Thalassemia | 2 | 1987 | 11 | 0.080 |
Why?
|
| Biological Factors | 1 | 1988 | 28 | 0.080 |
Why?
|
| Blood Cells | 3 | 2010 | 49 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2009 | 152 | 0.080 |
Why?
|
| Anemia, Aplastic | 3 | 2006 | 53 | 0.080 |
Why?
|
| Donor Selection | 1 | 2008 | 52 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2009 | 382 | 0.080 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 147 | 0.080 |
Why?
|
| DNA, Cruciform | 1 | 2008 | 18 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 2 | 2012 | 368 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2013 | 811 | 0.070 |
Why?
|
| Antigens, Fungal | 1 | 2007 | 34 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2024 | 278 | 0.070 |
Why?
|
| Chimera | 2 | 2003 | 88 | 0.070 |
Why?
|
| Cell Death | 3 | 2017 | 243 | 0.070 |
Why?
|
| Bone Density | 2 | 2001 | 311 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2006 | 1266 | 0.070 |
Why?
|
| Mitoxantrone | 2 | 2004 | 26 | 0.070 |
Why?
|
| Caspases | 2 | 2005 | 158 | 0.070 |
Why?
|
| Immunodominant Epitopes | 2 | 2012 | 50 | 0.070 |
Why?
|
| Thymidine Kinase | 2 | 1998 | 95 | 0.070 |
Why?
|
| Organ Specificity | 3 | 2018 | 423 | 0.070 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2007 | 12 | 0.070 |
Why?
|
| Injections, Subcutaneous | 3 | 2008 | 126 | 0.070 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 22 | 0.070 |
Why?
|
| DNA Mutational Analysis | 3 | 2011 | 793 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2008 | 130 | 0.070 |
Why?
|
| Adipocytes, Brown | 1 | 2007 | 27 | 0.070 |
Why?
|
| Chondrogenesis | 1 | 2007 | 26 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2008 | 145 | 0.070 |
Why?
|
| Pneumonia | 2 | 1987 | 325 | 0.070 |
Why?
|
| Cross Reactions | 2 | 2004 | 192 | 0.070 |
Why?
|
| HEK293 Cells | 3 | 2014 | 740 | 0.070 |
Why?
|
| Drug Resistance, Microbial | 4 | 1998 | 193 | 0.070 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2008 | 105 | 0.070 |
Why?
|
| Chondrocytes | 1 | 2007 | 49 | 0.070 |
Why?
|
| Serrate-Jagged Proteins | 2 | 2003 | 38 | 0.070 |
Why?
|
| Drug Design | 1 | 2008 | 146 | 0.070 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 41 | 0.070 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2001 | 39 | 0.070 |
Why?
|
| Jagged-1 Protein | 2 | 2003 | 51 | 0.070 |
Why?
|
| Cloning, Molecular | 3 | 2014 | 892 | 0.070 |
Why?
|
| Isoantigens | 2 | 2003 | 18 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 2025 | 0.070 |
Why?
|
| Immune System Diseases | 1 | 2006 | 43 | 0.070 |
Why?
|
| Benzimidazoles | 2 | 2004 | 129 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 298 | 0.070 |
Why?
|
| Antibody Specificity | 3 | 2001 | 202 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2477 | 0.060 |
Why?
|
| Regeneration | 1 | 1988 | 201 | 0.060 |
Why?
|
| HLA-A Antigens | 4 | 2011 | 35 | 0.060 |
Why?
|
| CD52 Antigen | 1 | 2005 | 7 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 1 | 2008 | 251 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2014 | 63 | 0.060 |
Why?
|
| Monocytes | 3 | 2012 | 346 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2005 | 263 | 0.060 |
Why?
|
| Pneumonia, Viral | 1 | 1991 | 376 | 0.060 |
Why?
|
| Age of Onset | 2 | 2011 | 581 | 0.060 |
Why?
|
| Vimentin | 2 | 1999 | 65 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 2 | 2003 | 327 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2003 | 281 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 2018 | 8106 | 0.060 |
Why?
|
| Virus Latency | 2 | 2006 | 61 | 0.060 |
Why?
|
| B7-1 Antigen | 1 | 2004 | 12 | 0.060 |
Why?
|
| OX40 Ligand | 1 | 2004 | 8 | 0.060 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2004 | 3 | 0.060 |
Why?
|
| Granzymes | 1 | 2004 | 37 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2005 | 313 | 0.060 |
Why?
|
| Lac Operon | 3 | 2001 | 94 | 0.060 |
Why?
|
| Cell-Free System | 4 | 1992 | 106 | 0.060 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2004 | 10 | 0.060 |
Why?
|
| Infection Control | 1 | 2006 | 160 | 0.060 |
Why?
|
| Neurons | 3 | 2001 | 1933 | 0.060 |
Why?
|
| Agammaglobulinemia | 1 | 1984 | 39 | 0.060 |
Why?
|
| Receptors, Notch | 2 | 2003 | 202 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 53 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2004 | 864 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 6 | 1990 | 68 | 0.060 |
Why?
|
| Cell Fusion | 1 | 2004 | 38 | 0.060 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2004 | 7 | 0.060 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 11 | 0.060 |
Why?
|
| Age Distribution | 1 | 2005 | 410 | 0.060 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 69 | 0.060 |
Why?
|
| CD4 Antigens | 2 | 2002 | 55 | 0.060 |
Why?
|
| Albumins | 1 | 2024 | 87 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2004 | 175 | 0.060 |
Why?
|
| Ethics Committees, Clinical | 1 | 2003 | 16 | 0.060 |
Why?
|
| Nuclear Family | 2 | 2001 | 50 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2024 | 121 | 0.050 |
Why?
|
| Bystander Effect | 1 | 2003 | 7 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 3 | 1998 | 69 | 0.050 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2003 | 60 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2003 | 38 | 0.050 |
Why?
|
| HLA-DP Antigens | 1 | 2002 | 5 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 260 | 0.050 |
Why?
|
| Mice, Nude | 3 | 2017 | 694 | 0.050 |
Why?
|
| Calcimycin | 5 | 1989 | 26 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2004 | 794 | 0.050 |
Why?
|
| Thymus Gland | 2 | 2004 | 99 | 0.050 |
Why?
|
| Spleen | 3 | 2006 | 272 | 0.050 |
Why?
|
| Antibody-Producing Cells | 2 | 1986 | 7 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 413 | 0.050 |
Why?
|
| Oxidopamine | 2 | 1999 | 15 | 0.050 |
Why?
|
| Dasatinib | 1 | 2022 | 41 | 0.050 |
Why?
|
| Vaccines, DNA | 1 | 2002 | 53 | 0.050 |
Why?
|
| Immunohistochemistry | 5 | 2008 | 1687 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 1994 | 258 | 0.050 |
Why?
|
| Macrophages | 2 | 2000 | 605 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2021 | 8 | 0.050 |
Why?
|
| Genes, myc | 1 | 2002 | 98 | 0.050 |
Why?
|
| Blast Crisis | 2 | 1992 | 17 | 0.050 |
Why?
|
| Polynucleotides | 1 | 2001 | 9 | 0.050 |
Why?
|
| United States | 6 | 2011 | 10631 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 2002 | 23 | 0.050 |
Why?
|
| Neutrophils | 2 | 2002 | 372 | 0.050 |
Why?
|
| Immunologic Surveillance | 1 | 2001 | 15 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2008 | 1388 | 0.050 |
Why?
|
| Phosphotransferases | 2 | 1992 | 41 | 0.050 |
Why?
|
| Quality of Life | 3 | 2024 | 1929 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 391 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2023 | 494 | 0.050 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2001 | 21 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 143 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 288 | 0.050 |
Why?
|
| Prednisone | 2 | 2014 | 274 | 0.050 |
Why?
|
| Day Care, Medical | 1 | 2001 | 9 | 0.050 |
Why?
|
| Hemocyanins | 2 | 1992 | 27 | 0.050 |
Why?
|
| Fractures, Spontaneous | 1 | 2001 | 18 | 0.050 |
Why?
|
| DNA Restriction Enzymes | 1 | 2001 | 120 | 0.050 |
Why?
|
| Leukopoiesis | 1 | 2000 | 3 | 0.050 |
Why?
|
| Viral Structural Proteins | 1 | 2001 | 47 | 0.050 |
Why?
|
| Psychomotor Disorders | 1 | 2001 | 28 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 2056 | 0.050 |
Why?
|
| Interferon-alpha | 2 | 1993 | 221 | 0.050 |
Why?
|
| Hematologic Diseases | 3 | 1995 | 78 | 0.050 |
Why?
|
| Disease Progression | 3 | 2017 | 2026 | 0.050 |
Why?
|
| Neutropenia | 3 | 1992 | 202 | 0.050 |
Why?
|
| HIV Infections | 2 | 2007 | 1869 | 0.050 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 14 | 0.040 |
Why?
|
| Dimerization | 2 | 2014 | 144 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 937 | 0.040 |
Why?
|
| Integrases | 1 | 2001 | 161 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 3 | 2006 | 51 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2000 | 66 | 0.040 |
Why?
|
| Pancytopenia | 2 | 2018 | 40 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 665 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 157 | 0.040 |
Why?
|
| Antigens, Differentiation | 3 | 1995 | 63 | 0.040 |
Why?
|
| Body Height | 1 | 2001 | 210 | 0.040 |
Why?
|
| Europe | 1 | 2001 | 374 | 0.040 |
Why?
|
| Neuroglia | 1 | 2001 | 193 | 0.040 |
Why?
|
| Utah | 1 | 1999 | 45 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 49 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 1992 | 393 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 49 | 0.040 |
Why?
|
| Postoperative Period | 4 | 1988 | 330 | 0.040 |
Why?
|
| CD40 Antigens | 1 | 1999 | 24 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2001 | 163 | 0.040 |
Why?
|
| Mifepristone | 1 | 1999 | 138 | 0.040 |
Why?
|
| Tetracycline | 1 | 1999 | 78 | 0.040 |
Why?
|
| Drug Therapy | 1 | 1999 | 87 | 0.040 |
Why?
|
| Thy-1 Antigens | 1 | 1999 | 21 | 0.040 |
Why?
|
| Norway | 1 | 1999 | 20 | 0.040 |
Why?
|
| Neurofilament Proteins | 1 | 1999 | 28 | 0.040 |
Why?
|
| Oligonucleotide Probes | 1 | 1999 | 85 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 2002 | 462 | 0.040 |
Why?
|
| Vaccines, Synthetic | 2 | 2004 | 312 | 0.040 |
Why?
|
| Batch Cell Culture Techniques | 1 | 2018 | 6 | 0.040 |
Why?
|
| Biopsy | 2 | 2020 | 1237 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 1998 | 29 | 0.040 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1998 | 13 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2015 | 697 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1999 | 211 | 0.040 |
Why?
|
| Treatment Failure | 1 | 1999 | 338 | 0.040 |
Why?
|
| Viral Load | 3 | 2004 | 383 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 1999 | 108 | 0.040 |
Why?
|
| Gene Amplification | 2 | 2002 | 228 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 28 | 0.040 |
Why?
|
| RNA, Catalytic | 1 | 1998 | 15 | 0.040 |
Why?
|
| Graft vs Tumor Effect | 1 | 1998 | 7 | 0.040 |
Why?
|
| Retinal Neoplasms | 1 | 1999 | 98 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 28 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 77 | 0.040 |
Why?
|
| Mice, Inbred A | 1 | 1997 | 12 | 0.040 |
Why?
|
| Forecasting | 2 | 1996 | 354 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2018 | 93 | 0.040 |
Why?
|
| Gammaretrovirus | 1 | 2017 | 5 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2001 | 366 | 0.040 |
Why?
|
| Sirolimus | 1 | 1999 | 220 | 0.040 |
Why?
|
| Chromatin | 2 | 2015 | 552 | 0.040 |
Why?
|
| beta-Galactosidase | 3 | 2004 | 145 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 1997 | 99 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 647 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 262 | 0.040 |
Why?
|
| HLA-A2 Antigen | 2 | 2011 | 24 | 0.040 |
Why?
|
| X Chromosome | 1 | 1998 | 337 | 0.040 |
Why?
|
| Hot Temperature | 1 | 1998 | 136 | 0.040 |
Why?
|
| Eye Proteins | 1 | 1999 | 218 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 58 | 0.040 |
Why?
|
| Cell Hypoxia | 2 | 2008 | 94 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2017 | 35 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2014 | 312 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 3 | 1998 | 2394 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 59 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 88 | 0.030 |
Why?
|
| Consumer Product Safety | 1 | 1996 | 29 | 0.030 |
Why?
|
| Centrifugation | 1 | 2016 | 25 | 0.030 |
Why?
|
| Brain | 4 | 2002 | 2961 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2001 | 996 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2002 | 2047 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 253 | 0.030 |
Why?
|
| Interleukin-3 | 2 | 1999 | 17 | 0.030 |
Why?
|
| Receptors, Dopamine | 2 | 1987 | 40 | 0.030 |
Why?
|
| Genes, Dominant | 2 | 2008 | 248 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2016 | 58 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 237 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2016 | 61 | 0.030 |
Why?
|
| Benzazepines | 2 | 1987 | 64 | 0.030 |
Why?
|
| P-Selectin | 1 | 2016 | 77 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2016 | 70 | 0.030 |
Why?
|
| HLA-DR Antigens | 3 | 1996 | 74 | 0.030 |
Why?
|
| Liver | 2 | 2003 | 1734 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1996 | 29 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2016 | 96 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 25 | 0.030 |
Why?
|
| Vaccination | 2 | 2007 | 951 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2001 | 459 | 0.030 |
Why?
|
| Membrane Lipids | 1 | 1995 | 33 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1998 | 170 | 0.030 |
Why?
|
| Glycolipids | 1 | 1995 | 33 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 87 | 0.030 |
Why?
|
| Seizures | 1 | 2001 | 874 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 11 | 0.030 |
Why?
|
| Th2 Cells | 2 | 2009 | 187 | 0.030 |
Why?
|
| Conserved Sequence | 2 | 2007 | 293 | 0.030 |
Why?
|
| Mitosis | 1 | 1996 | 238 | 0.030 |
Why?
|
| Supratentorial Neoplasms | 1 | 1995 | 37 | 0.030 |
Why?
|
| Globins | 1 | 1995 | 35 | 0.030 |
Why?
|
| Incidence | 3 | 2018 | 3047 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2014 | 9 | 0.030 |
Why?
|
| Luciferases, Firefly | 1 | 2014 | 14 | 0.030 |
Why?
|
| Jurkat Cells | 2 | 2005 | 76 | 0.030 |
Why?
|
| Pokeweed Mitogens | 3 | 1987 | 3 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 73 | 0.030 |
Why?
|
| RNA | 1 | 1998 | 572 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 338 | 0.030 |
Why?
|
| Age Factors | 2 | 2011 | 2802 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 41 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1999 | 593 | 0.030 |
Why?
|
| Informed Consent | 2 | 1994 | 341 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 905 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1996 | 313 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 38 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 43 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 1999 | 3718 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 113 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 603 | 0.030 |
Why?
|
| Bronchiolitis Obliterans | 1 | 1994 | 39 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 1996 | 452 | 0.030 |
Why?
|
| Cyclosporine | 2 | 2006 | 146 | 0.030 |
Why?
|
| Restriction Mapping | 2 | 1990 | 188 | 0.030 |
Why?
|
| Transcobalamins | 1 | 1993 | 4 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 459 | 0.030 |
Why?
|
| Drug Evaluation | 2 | 1990 | 111 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 549 | 0.030 |
Why?
|
| Asthma | 1 | 2001 | 745 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2013 | 33 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 73 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 360 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 1993 | 55 | 0.030 |
Why?
|
| Blood Donors | 2 | 2011 | 62 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1996 | 395 | 0.030 |
Why?
|
| Cell Count | 2 | 1996 | 250 | 0.030 |
Why?
|
| Organoids | 1 | 2016 | 277 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 123 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 131 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 747 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 1999 | 1116 | 0.030 |
Why?
|
| Research | 1 | 1994 | 263 | 0.030 |
Why?
|
| Immunoradiometric Assay | 1 | 1992 | 4 | 0.030 |
Why?
|
| CD11 Antigens | 1 | 1992 | 12 | 0.030 |
Why?
|
| Suspensions | 1 | 2012 | 9 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1993 | 206 | 0.030 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 1992 | 11 | 0.030 |
Why?
|
| Mollusca | 1 | 1992 | 9 | 0.030 |
Why?
|
| Reference Values | 1 | 1994 | 697 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2012 | 89 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 257 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1740 | 0.020 |
Why?
|
| Sex Factors | 1 | 1996 | 1259 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1994 | 147 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 114 | 0.020 |
Why?
|
| Sibling Relations | 1 | 2011 | 13 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 1991 | 14 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 224 | 0.020 |
Why?
|
| Injections | 1 | 2012 | 153 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 280 | 0.020 |
Why?
|
| Probability | 1 | 1992 | 321 | 0.020 |
Why?
|
| Bacterial Infections | 2 | 1996 | 305 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1019 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 586 | 0.020 |
Why?
|
| TATA Box | 1 | 1990 | 25 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 1991 | 69 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 1991 | 41 | 0.020 |
Why?
|
| Immune Evasion | 1 | 2011 | 34 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 154 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1990 | 143 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2011 | 170 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 115 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 13 | 0.020 |
Why?
|
| Plasma Cells | 1 | 1990 | 54 | 0.020 |
Why?
|
| Blotting, Northern | 3 | 2001 | 258 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1990 | 151 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1989 | 35 | 0.020 |
Why?
|
| Research Design | 1 | 1994 | 685 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 148 | 0.020 |
Why?
|
| Vaccines | 1 | 1995 | 369 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2008 | 809 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 51 | 0.020 |
Why?
|
| Telomerase | 1 | 2010 | 161 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 235 | 0.020 |
Why?
|
| Chemokine CCL19 | 1 | 2009 | 6 | 0.020 |
Why?
|
| MART-1 Antigen | 1 | 2009 | 13 | 0.020 |
Why?
|
| Netilmicin | 1 | 1989 | 1 | 0.020 |
Why?
|
| Chemokine CCL22 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Chemokine CCL17 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2009 | 16 | 0.020 |
Why?
|
| Penicillin G | 1 | 1989 | 19 | 0.020 |
Why?
|
| Reed-Sternberg Cells | 1 | 2009 | 7 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 1989 | 14 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 405 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 1989 | 26 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 279 | 0.020 |
Why?
|
| Tartrates | 1 | 1988 | 2 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 1988 | 11 | 0.020 |
Why?
|
| Genome, Human | 1 | 2015 | 1267 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1992 | 334 | 0.020 |
Why?
|
| National Health Programs | 1 | 2008 | 19 | 0.020 |
Why?
|
| Alleles | 2 | 2004 | 1603 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 795 | 0.020 |
Why?
|
| Philadelphia Chromosome | 1 | 2008 | 40 | 0.020 |
Why?
|
| RNA, Neoplasm | 4 | 1991 | 138 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2011 | 372 | 0.020 |
Why?
|
| Cricetinae | 1 | 1989 | 408 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 3543 | 0.020 |
Why?
|
| Thymidine | 1 | 1988 | 54 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 1988 | 57 | 0.020 |
Why?
|
| Terminal Repeat Sequences | 1 | 2008 | 18 | 0.020 |
Why?
|
| Preoperative Care | 2 | 1989 | 350 | 0.020 |
Why?
|
| Antibodies | 1 | 2009 | 369 | 0.020 |
Why?
|
| Drug Synergism | 4 | 1989 | 239 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2008 | 55 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1988 | 79 | 0.020 |
Why?
|
| Response Elements | 1 | 2008 | 97 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1989 | 214 | 0.020 |
Why?
|
| Luciferases | 1 | 2008 | 137 | 0.020 |
Why?
|
| Daunorubicin | 2 | 2001 | 27 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 2000 | 214 | 0.020 |
Why?
|
| Hepatitis B | 1 | 1989 | 159 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 501 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 354 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2007 | 18 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 22 | 0.020 |
Why?
|
| Cytotoxins | 1 | 1987 | 20 | 0.020 |
Why?
|
| Cell Cycle | 2 | 2001 | 614 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 130 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 1987 | 57 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1989 | 301 | 0.020 |
Why?
|
| Feedback | 1 | 1988 | 162 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2006 | 11 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 84 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 1998 | 252 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 1067 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1793 | 0.020 |
Why?
|
| Carrier State | 2 | 2002 | 76 | 0.020 |
Why?
|
| Cystitis | 1 | 1987 | 50 | 0.020 |
Why?
|
| Moloney murine leukemia virus | 2 | 1998 | 19 | 0.020 |
Why?
|
| Biological Products | 1 | 1988 | 113 | 0.020 |
Why?
|
| Blood Group Incompatibility | 1 | 1986 | 27 | 0.020 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1986 | 28 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 94 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 1986 | 65 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 124 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 1430 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 350 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 1986 | 197 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1215 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1989 | 550 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 1986 | 159 | 0.020 |
Why?
|
| Receptors, OX40 | 1 | 2005 | 7 | 0.020 |
Why?
|
| Chromium | 1 | 2005 | 6 | 0.020 |
Why?
|
| Dopamine | 1 | 1987 | 275 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1990 | 1695 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2005 | 33 | 0.020 |
Why?
|
| Texas | 1 | 2013 | 3555 | 0.020 |
Why?
|
| Polylysine | 1 | 2004 | 10 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2004 | 31 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 56 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2005 | 131 | 0.010 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2004 | 9 | 0.010 |
Why?
|
| COS Cells | 1 | 2005 | 273 | 0.010 |
Why?
|
| Methotrexate | 1 | 2006 | 341 | 0.010 |
Why?
|
| Serotyping | 1 | 2004 | 178 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1984 | 96 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2004 | 78 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2004 | 59 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 33 | 0.010 |
Why?
|
| Leukemia Virus, Gibbon Ape | 1 | 2003 | 1 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1987 | 459 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2004 | 213 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 16 | 0.010 |
Why?
|
| Random Allocation | 3 | 1989 | 427 | 0.010 |
Why?
|
| Biological Transport | 1 | 2004 | 347 | 0.010 |
Why?
|
| Herpesvirus 1, Human | 1 | 2003 | 26 | 0.010 |
Why?
|
| Vero Cells | 1 | 2003 | 110 | 0.010 |
Why?
|
| Culture Media | 1 | 1983 | 182 | 0.010 |
Why?
|
| HLA-DP beta-Chains | 1 | 2002 | 9 | 0.010 |
Why?
|
| Tetanus | 1 | 1983 | 21 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2002 | 33 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 171 | 0.010 |
Why?
|
| Panniculitis | 1 | 2002 | 19 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 102 | 0.010 |
Why?
|
| Minichromosome Maintenance Complex Component 7 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2002 | 49 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 230 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 12 | 0.010 |
Why?
|
| Etoposide | 2 | 1992 | 117 | 0.010 |
Why?
|
| Pediatrics | 1 | 2011 | 1138 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 2002 | 28 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 533 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 78 | 0.010 |
Why?
|
| Attachment Sites, Microbiological | 1 | 2001 | 7 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 240 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2003 | 225 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 1984 | 263 | 0.010 |
Why?
|
| HLA-A11 Antigen | 1 | 2001 | 3 | 0.010 |
Why?
|
| DNA Probes | 2 | 1992 | 123 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 126 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 99 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 375 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2001 | 356 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 62 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 614 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1999 | 7 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 657 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2000 | 71 | 0.010 |
Why?
|
| Janus Kinase 3 | 1 | 1999 | 16 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 151 | 0.010 |
Why?
|
| Alu Elements | 1 | 2000 | 64 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 505 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 623 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 661 | 0.010 |
Why?
|
| Public Policy | 1 | 1999 | 51 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 1999 | 12 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1999 | 47 | 0.010 |
Why?
|
| Phosphatidylethanolamines | 1 | 1998 | 22 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1999 | 132 | 0.010 |
Why?
|
| Rituximab | 1 | 2000 | 155 | 0.010 |
Why?
|
| Microinjections | 1 | 1998 | 52 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2000 | 442 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2001 | 527 | 0.010 |
Why?
|
| RNA, Transfer, Amino Acyl | 1 | 1998 | 5 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1998 | 12 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 1999 | 150 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2002 | 809 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 1998 | 72 | 0.010 |
Why?
|
| Bone Diseases | 1 | 1998 | 45 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1999 | 359 | 0.010 |
Why?
|
| HIV | 1 | 1999 | 179 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1998 | 330 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1998 | 348 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 368 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1996 | 13 | 0.010 |
Why?
|
| Resource Allocation | 1 | 1996 | 52 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1998 | 262 | 0.010 |
Why?
|
| Health Care Rationing | 1 | 1996 | 58 | 0.010 |
Why?
|
| Drug Industry | 1 | 1995 | 46 | 0.010 |
Why?
|
| Genetic Research | 1 | 1996 | 56 | 0.010 |
Why?
|
| Rabbits | 2 | 1987 | 708 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1998 | 541 | 0.010 |
Why?
|
| Internationality | 1 | 1996 | 130 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 3249 | 0.010 |
Why?
|
| Binding Sites | 1 | 1998 | 1291 | 0.010 |
Why?
|
| Laboratories | 1 | 1995 | 83 | 0.010 |
Why?
|
| Universities | 1 | 1995 | 126 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1995 | 85 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 1995 | 76 | 0.010 |
Why?
|
| Intelligence | 1 | 1995 | 98 | 0.010 |
Why?
|
| Mycoses | 1 | 1996 | 117 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2001 | 1682 | 0.010 |
Why?
|
| Autoradiography | 1 | 1994 | 71 | 0.010 |
Why?
|
| Self Concept | 1 | 1995 | 157 | 0.010 |
Why?
|
| Myelin Proteins | 1 | 1994 | 76 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1994 | 473 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 867 | 0.010 |
Why?
|
| Plasma | 1 | 1993 | 96 | 0.010 |
Why?
|
| alpha-Macroglobulins | 1 | 1992 | 7 | 0.010 |
Why?
|
| Enkephalins | 1 | 1992 | 20 | 0.010 |
Why?
|
| Survivors | 1 | 1995 | 345 | 0.010 |
Why?
|
| Transferrin | 1 | 1992 | 51 | 0.010 |
Why?
|
| S100 Proteins | 1 | 1992 | 46 | 0.010 |
Why?
|
| Amsacrine | 1 | 1992 | 5 | 0.010 |
Why?
|
| 2-Chloroadenosine | 1 | 1992 | 6 | 0.010 |
Why?
|
| Cladribine | 1 | 1992 | 8 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 586 | 0.010 |
Why?
|
| Deoxyadenosines | 1 | 1992 | 9 | 0.010 |
Why?
|
| Azacitidine | 1 | 1992 | 54 | 0.010 |
Why?
|
| Cytarabine | 1 | 1992 | 98 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1992 | 149 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1992 | 105 | 0.010 |
Why?
|
| Neprilysin | 1 | 1991 | 19 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1995 | 923 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1992 | 167 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 1992 | 197 | 0.010 |
Why?
|
| Transcription Factor TFIID | 1 | 1990 | 13 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 1990 | 49 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1990 | 79 | 0.010 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1990 | 62 | 0.010 |
Why?
|
| Cognition | 1 | 1995 | 735 | 0.010 |
Why?
|
| Y Chromosome | 1 | 1990 | 47 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1990 | 319 | 0.010 |
Why?
|
| United Kingdom | 1 | 1990 | 191 | 0.010 |
Why?
|
| Azlocillin | 1 | 1989 | 1 | 0.010 |
Why?
|
| Piperacillin | 1 | 1989 | 13 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 396 | 0.010 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1989 | 6 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1990 | 300 | 0.010 |
Why?
|
| beta-Lactams | 1 | 1989 | 50 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1989 | 64 | 0.000 |
Why?
|
| Herpes Zoster | 1 | 1989 | 24 | 0.000 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 1988 | 1 | 0.000 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1990 | 297 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1988 | 151 | 0.000 |
Why?
|
| Rauscher Virus | 1 | 1968 | 2 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1988 | 185 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1988 | 391 | 0.000 |
Why?
|
| Host vs Graft Reaction | 1 | 1988 | 1 | 0.000 |
Why?
|
| Immune Sera | 1 | 1968 | 95 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1990 | 771 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1988 | 179 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1989 | 186 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1988 | 223 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1990 | 422 | 0.000 |
Why?
|
| Stroke Volume | 1 | 1989 | 445 | 0.000 |
Why?
|
| Protein Kinase C | 1 | 1988 | 150 | 0.000 |
Why?
|
| Interleukins | 1 | 1988 | 118 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1986 | 30 | 0.000 |
Why?
|
| Indicators and Reagents | 1 | 1987 | 51 | 0.000 |
Why?
|
| Risk Assessment | 1 | 1996 | 3316 | 0.000 |
Why?
|
| Ficoll | 1 | 1986 | 1 | 0.000 |
Why?
|
| Hematuria | 1 | 1987 | 50 | 0.000 |
Why?
|
| Metrizoic Acid | 1 | 1986 | 2 | 0.000 |
Why?
|
| Adenylyl Cyclases | 1 | 1987 | 75 | 0.000 |
Why?
|
| Coombs Test | 1 | 1986 | 6 | 0.000 |
Why?
|
| Alkylation | 1 | 1986 | 10 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1986 | 58 | 0.000 |
Why?
|
| Fenoldopam | 1 | 1986 | 11 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1986 | 76 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1990 | 1414 | 0.000 |
Why?
|
| Caudate Nucleus | 1 | 1986 | 35 | 0.000 |
Why?
|
| Lung | 1 | 1994 | 1475 | 0.000 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1989 | 797 | 0.000 |
Why?
|
| Norepinephrine | 1 | 1986 | 175 | 0.000 |
Why?
|
| Radiation Dosage | 1 | 1986 | 134 | 0.000 |
Why?
|
| Bilirubin | 1 | 1986 | 120 | 0.000 |
Why?
|
| DNA Replication | 1 | 1987 | 342 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1987 | 288 | 0.000 |
Why?
|
| Immunization, Secondary | 1 | 1986 | 105 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1986 | 247 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1989 | 1151 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1987 | 567 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1989 | 1589 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1990 | 976 | 0.000 |
Why?
|
| Myocardium | 1 | 1989 | 984 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1986 | 424 | 0.000 |
Why?
|
| Methods | 1 | 1968 | 147 | 0.000 |
Why?
|
| Haplorhini | 1 | 1968 | 123 | 0.000 |
Why?
|
| Kidney | 1 | 1968 | 1337 | 0.000 |
Why?
|